\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ and\\ laboratory\\:\\ \ \(0\)\
\-\ normal\\ physical\\ exam\\ except\\ for\\ bilateral\\ decreased\\ range\\ of\\ motion\\ of\\ the\\ hips\\ and\\ atalgic\\ gait\\ secondary\\ to\\ hip\\ pain\\.\\ \\ laboratory\\ studies\\ showed\\ mild\\ macrocytic\\ anemia\\ and\\ leukopenia\\.\ \(0\)\
\-\ treatment\\ and\\ follow\\-up\\:\\ the\\ patient\\ is\\ currently\\ receiving\\ chemotherapy\\ via\\ the\\ pog\\ 9906\\ protocol\\,\\ currently\\ a\\ phase\\ iii\\ randomized\\ study\\ of\\ multidrug\\ antimetabolite\\ therapy\\ in\\ children\\ recently\\ diagnosed\\ with\\ acute\\ lymphoblastic\\ leukemia\\ designated\\ as\\ high\\ risk\\.\\ \\ the\\ protocol\\ specifies\\ a\\ number\\ of\\ short\\ bursts\\ of\\ steroids\\ over\\ the\\ course\\ of\\ the\\ 130\\-week\\ regimen\\,\\ which\\ has\\ been\\ halted\\ in\\ this\\ patient\\.\ \(0\)\
\-\ imaging\\ findings\\:\\ anteroposterior\\ \\(ap\\)\\ radiograph\\ of\\ the\\ hips\\ at\\ presentation\\ was\\ normal\\ and\\ showed\\ normal\\ mineralization\\ with\\ no\\ evidence\\ of\\ subluxation\\,\\ dislocation\\,\\ fractures\\,\\ or\\ osteoblastic\\/osteolytic\\ changes\\.\\ \\ magnetic\\ resonance\\ \\(mr\\)\\ imaging\\ of\\ both\\ the\\ right\\ and\\ left\\ hips\\ demonstrated\\ subchondral\\ low\\ signal\\ intensity\\ of\\ the\\ femoral\\ head\\ on\\ coronal\\ t1\\ imaging\\,\\ best\\ seen\\ on\\ the\\ left\\,\\ that\\ becomes\\ high\\ signal\\ intensity\\ on\\ a\\ coronal\\ stir\\ \\(fat\\ suppressed\\)\\ image\\.\\ \\ there\\ was\\ also\\ increased\\ signal\\ intensity\\ of\\ the\\ femoral\\ neck\\,\\ particularly\\ the\\ lateral\\ margin\\,\\ on\\ stir\\ imaging\\.\\ \\ a\\ subsequent\\ ap\\ hip\\ radiograph\\ 2\\ months\\ after\\ presentation\\ shows\\ new\\ subchondral\\ fracture\\ lucencies\\ in\\ the\\ right\\ and\\ left\\ femoral\\ heads\\ and\\ mild\\ flattening\\ of\\ the\\ left\\ superior\\ head\\ along\\ with\\ bilateral\\ preserved\\ joint\\ space\\.\\ \\ a\\ year\\ after\\ presentation\\,\\ an\\ ap\\ hip\\ radiograph\\ showed\\ an\\ increase\\ in\\ collapse\\ of\\ the\\ left\\ femoral\\ head\\ and\\ bilateral\\ early\\ degenerative\\ change\\ of\\ the\\ hips\\.\ \(0\)\
\-\ avascular\\ necrosis\\ of\\ hip\ \(0\)\
\-\ differential\\ diagnosis\\ for\\ these\\ findings\\ in\\ this\\ case\\:\ \(0\)\
\-\ avascular\\ necrosis\\ secondary\\ to\\ steroid\\ therapy\ \(0\)\
\-\ history\\ \\(can\\ include\\ gestational\\ age\\,\\ or\\ age\\ in\\ days\\,\\ weeks\\,\\ months\\)\\:\\ 18\\ year\\ old\\ male\\ with\\ a\\ 1\\ year\\ history\\ of\\ pre\\ b\\-cell\\ acute\\ lymphocytic\\ leukemia\\ currently\\ on\\ chemotherapy\\ protocol\\ that\\ includes\\ treatment\\ with\\ vincristine\\,\\ methotrexate\\,\\ prednisone\\/dexamethasone\\ surges\\,\\ and\\ 6\\-mp\\.\\ patient\\ complains\\ of\\ recent\\ onset\\ of\\ bilateral\\ hip\\ pain\\.\ \(0\)\
\-\ discussion\\ \\(include\\ references\\)\\:\\ avascular\\ necrosis\\ of\\ the\\ hip\\ may\\ be\\ a\\ difficult\\ diagnosis\\ to\\ make\\ when\\ a\\ patient\\ first\\ presents\\ with\\ hip\\ pain\\ or\\ mild\\ gait\\ abnormalities\\.\\ \\ initial\\ radiographs\\ of\\ the\\ hips\\ may\\ no\\ show\\ no\\ changes\\,\\ as\\ in\\ this\\ case\\.\\ \\ therefore\\,\\ clinical\\ suspicion\\ should\\ be\\ high\\ for\\ this\\ disorder\\ in\\ a\\ patient\\ whose\\ history\\ suggests\\ the\\ diagnosis\\.\\ \\ avascular\\ necrosis\\ is\\ caused\\ by\\ a\\ number\\ of\\ etiologies\\ including\\ femoral\\ neck\\ fracture\\,\\ alcohol\\ use\\,\\ sickle\\ cell\\ disease\\,\\ systemic\\ lupus\\ erythematosus\\,\\ radiation\\ treatment\\,\\ and\\ prolonged\\ corticosteroid\\ administration\\,\\ as\\ in\\ this\\ patient\\.\\ \\ steroids\\ have\\ been\\ implicated\\ in\\ about\\ 20\\ to\\ 35\\ percent\\ of\\ cases\\.\\ \\ the\\ occurrence\\ also\\ appears\\ to\\ be\\ directly\\ related\\ to\\ the\\ dosage\\ level\\ and\\ duration\\ of\\ the\\ medication\\.\\ \\ in\\ decreasing\\ order\\ of\\ frequency\\,\\ the\\ most\\ common\\ locations\\ of\\ steroid\\-induced\\ avasular\\ osteonecrosis\\ are\\ the\\ femoral\\ head\\,\\ humeral\\ head\\,\\ the\\ distal\\ end\\ of\\ the\\ femur\\,\\ and\\ the\\ proximal\\ part\\ of\\ the\\ tibia\\.\\ \\ \ \(0\)\
\-\ the\\ pathogenesis\\ of\\ steroid\\-induced\\ osteonecrosis\\ is\\ unclear\\.\\ \\ however\\ several\\ mechanisms\\ have\\ been\\ proposed\\ and\\ include\\ both\\ mechanical\\ and\\ vascular\\ etiologies\\.\\ \\ osteoporosis\\ resulting\\ in\\ microfractures\\ and\\ later\\ bone\\ collapse\\ is\\ one\\ mechanical\\ theory\\.\\ \\ vascular\\ compromise\\ due\\ to\\ hyperviscosity\\,\\ vasculitis\\,\\ fat\\ embolization\\,\\ and\\ compression\\ from\\ marrow\\ accumulation\\ of\\ relatively\\ inelastic\\ fat\\ cells\\ are\\ also\\ other\\ possible\\ causes\\.\ \(0\)\
\-\ \\ \\ \ \(31891\)\
\-\ the\\ most\\ common\\ presenting\\ symptom\\ of\\ avascular\\ necrosis\\ is\\ pain\\.\\ \\ groin\\ pain\\ and\\ less\\ commonly\\ thigh\\ and\\ buttock\\ pain\\ are\\ seen\\ in\\ patients\\ with\\ femoral\\ head\\ involvement\\.\\ \\ patients\\ may\\ also\\ complain\\ of\\ pain\\ upon\\ weight\\ bearing\\.\\ \\ thirty\\ to\\ fifty\\ percent\\ have\\ bilateral\\ involvement\\.\\ \\ physical\\ exam\\ usually\\ is\\ nonspecific\\ and\\ may\\ demonstrate\\ limited\\ range\\ of\\ motion\\ particularly\\ in\\ abduction\\ and\\ internal\\ rotation\\.\ \(0\)\
\-\ radiographic\\ evaluation\\ of\\ a\\ patient\\ with\\ suspected\\ osteonecrosis\\ includes\\ an\\ ap\\ and\\ frog\\-leg\\ radiograph\\ of\\ both\\ hips\\.\\ \\ as\\ mentioned\\ above\\,\\ the\\ initial\\ radiographs\\ may\\ not\\ show\\ any\\ evidence\\ of\\ disease\\.\\ \\ subsequently\\,\\ radiographic\\ findings\\ show\\ sclerosis\\,\\ indistinctive\\ trabecular\\ pattern\\,\\ and\\ patchy\\ osteoporosis\\.\\ \\ progressive\\ radiograph\\ findings\\ include\\ a\\ crescentic\\ subchondral\\ line\\ indicative\\ of\\ subchondral\\ collapse\\,\\ segmental\\ flattening\\ of\\ the\\ femoral\\ head\\,\\ and\\ ultimately\\ joint\\ space\\ narrowing\\,\\ acetabular\\ degenerative\\ changes\\,\\ and\\ collapse\\ of\\ the\\ femoral\\ head\\.\ \(0\)\
\-\ mr\\ imaging\\ is\\ the\\ most\\ sensitive\\ test\\ for\\ detecting\\ avascular\\ necrosis\\.\\ \\ as\\ with\\ this\\ patient\\,\\ mr\\ imaging\\ showed\\ evidence\\ of\\ osteonecrosis\\ prior\\ to\\ the\\ radiographs\\.\\ \\ t1\\-weighted\\ images\\ typically\\ show\\ a\\ line\\ of\\ low\\ signal\\ intensity\\,\\ which\\ corresponds\\ to\\ the\\ presence\\ of\\ granulation\\ tissue\\ and\\ sclerotic\\ bone\\.\\ \\ t2\\-weighted\\ images\\ typically\\ demonstrate\\ a\\ double\\ line\\ sign\\,\\ which\\ consists\\ of\\ a\\ narrower\\ line\\ of\\ low\\ signal\\ intensity\\ that\\ corresponds\\ to\\ bone\\ sclerosis\\ and\\ an\\ inner\\ zone\\ of\\ high\\ signal\\ intensity\\ that\\ corresponds\\ to\\ granulation\\ tissue\\.\\ \\ \\ \ \(0\)\
\-\ references\ \(24\)\
\-\ laporte\\ et\\ al\\.\\ \\ \\‚\\Ä\\úmultifocal\\ osteonecrosis\\.\\‚\\Ä\\ù\\ \\ journal\\ of\\ rheumatology\\.\\ \\ 25\\(10\\)\\,\\ oct\\ 1998\\,\\ pp\\ 1968\\-74\\.\\ \ \(0\)\
\-\ donald\\ resnick\\.\\ \\ diagnosis\\ of\\ bone\\ and\\ joint\\ disorders\\.\\ \\ philadelphia\\:\\ w\\.b\\.\\ saunders\\ co\\.\\ 2002\\.\\ pp\\.\\ 3599\\-3637\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ of\\:\\ 0\\.2797672972401418\ \(0\)\
\-\ the\\:\\ 0\\.22324533166518465\ \(0\)\
\-\ femoral\\:\\ 0\\.207888442394655\ \(0\)\
\-\ hips\\:\\ 0\\.19642857277333375\ \(0\)\
\-\ avascular\\:\\ 0\\.18542961894824525\ \(0\)\
\-\ and\\:\\ 0\\.1798149609698933\ \(0\)\
\-\ osteonecrosis\\:\\ 0\\.16976910072126586\ \(0\)\
\-\ hip\\:\\ 0\\.16711515570591665\ \(0\)\
\-\ head\\:\\ 0\\.1482865376623599\ \(0\)\
\-\ necrosis\\:\\ 0\\.14253550784095578\ \(0\)\
\-\ intensity\\:\\ 0\\.13240615595826608\ \(0\)\
\-\ subchondral\\:\\ 0\\.11896539133780198\ \(0\)\
\-\ collapse\\:\\ 0\\.11658564478056983\ \(0\)\
\-\ in\\:\\ 0\\.10823802772947169\ \(0\)\
\-\ signal\\:\\ 0\\.10570463687862043\ \(0\)\
\-\ corresponds\\:\\ 0\\.1048414186079603\ \(0\)\
\-\ radiograph\\:\\ 0\\.1012092907199246\ \(0\)\
\-\ imaging\\:\\ 0\\.09799638406557537\ \(0\)\
\-\ line\\:\\ 0\\.09686914434773039\ \(0\)\
\-\ to\\:\\ 0\\.09323435162515119\ \(0\)\
\-\ protocol\\:\\ 0\\.09099274250903668\ \(0\)\
\-\ steroid\\:\\ 0\\.08986508720028749\ \(0\)\
\-\ ap\\:\\ 0\\.08924881197995352\ \(0\)\
\-\ bilateral\\:\\ 0\\.08351329118473452\ \(0\)\
\-\ showed\\:\\ 0\\.08280154461022181\ \(0\)\
\-\ patient\\:\\ 0\\.08086584634813195\ \(0\)\
\-\ show\\:\\ 0\\.0789170357696526\ \(0\)\
\-\ granulation\\:\\ 0\\.07819882085219311\ \(0\)\
\-\ may\\:\\ 0\\.0781980571024516\ \(0\)\
\-\ pain\\:\\ 0\\.07784687002745966\ \(0\)\
\-\ include\\:\\ 0\\.07396536831516388\ \(0\)\
\-\ currently\\:\\ 0\\.07162078101682141\ \(0\)\
\-\ high\\:\\ 0\\.07065161732373806\ \(0\)\
\-\ stir\\:\\ 0\\.07026368211220065\ \(0\)\
\-\ pp\\:\\ 0\\.07026368211220065\ \(0\)\
\-\ bone\\:\\ 0\\.0678292905142075\ \(0\)\
\-\ osteoporosis\\:\\ 0\\.06622796113027737\ \(0\)\
\-\ diagnosis\\:\\ 0\\.06444320908932352\ \(0\)\
\-\ presentation\\:\\ 0\\.06418147580089038\ \(0\)\
\-\ this\\:\\ 0\\.0640745079095277\ \(0\)\
\-\ as\\:\\ 0\\.0624264037807842\ \(0\)\
\-\ etiologies\\:\\ 0\\.062341507497586754\ \(0\)\
\-\ mechanical\\:\\ 0\\.06163827343479069\ \(0\)\
\-\ percent\\:\\ 0\\.06146933445236818\ \(0\)\
\-\ joint\\:\\ 0\\.06143713207242089\ \(0\)\
\-\ findings\\:\\ 0\\.061353671637705554\ \(0\)\
\-\ flattening\\:\\ 0\\.06130297479203023\ \(0\)\
\-\ radiographs\\:\\ 0\\.06047103840017195\ \(0\)\
\-\ mr\\:\\ 0\\.06032734939436786\ \(0\)\
\-\ is\\:\\ 0\\.059577142906927935\ \(0\)\
\-\ particularly\\:\\ 0\\.058675189555890586\ \(0\)\
\-\ also\\:\\ 0\\.058473482068188934\ \(0\)\
\-\ fat\\:\\ 0\\.0579979749829976\ \(0\)\
\-\ number\\:\\ 0\\.05722018528726174\ \(0\)\
\-\ leukemia\\:\\ 0\\.05677537470666717\ \(0\)\
\-\ changes\\:\\ 0\\.056347396948138825\ \(0\)\
\-\ with\\:\\ 0\\.05476978528700437\ \(0\)\
\-\ steroids\\:\\ 0\\.054608626928425295\ \(0\)\
\-\ been\\:\\ 0\\.0543198160572122\ \(0\)\
\-\ that\\:\\ 0\\.05394737343808426\ \(0\)\
\-\ gait\\:\\ 0\\.05383306556446117\ \(0\)\
\-\ low\\:\\ 0\\.05349879612060713\ \(0\)\
\-\ left\\:\\ 0\\.053007534459118225\ \(0\)\
\-\ evidence\\:\\ 0\\.052920373440379635\ \(0\)\
\-\ mild\\:\\ 0\\.052852318439310216\ \(0\)\
\-\ degenerative\\:\\ 0\\.05280209713973279\ \(0\)\
\-\ both\\:\\ 0\\.051992462397294416\ \(0\)\
\-\ physical\\:\\ 0\\.05055420294833386\ \(0\)\
\-\ atalgic\\:\\ 0\\.04970106565336229\ \(0\)\
\-\ macrocytic\\:\\ 0\\.04970106565336229\ \(0\)\
\-\ pog\\:\\ 0\\.04970106565336229\ \(0\)\
\-\ 9906\\:\\ 0\\.04970106565336229\ \(0\)\
\-\ multidrug\\:\\ 0\\.04970106565336229\ \(0\)\
\-\ antimetabolite\\:\\ 0\\.04970106565336229\ \(0\)\
\-\ specifies\\:\\ 0\\.04970106565336229\ \(0\)\
\-\ halted\\:\\ 0\\.04970106565336229\ \(0\)\
\-\ avasular\\:\\ 0\\.04970106565336229\ \(0\)\
\-\ microfractures\\:\\ 0\\.04970106565336229\ \(0\)\
\-\ hyperviscosity\\:\\ 0\\.04970106565336229\ \(0\)\
\-\ inelastic\\:\\ 0\\.04970106565336229\ \(0\)\
\-\ indistinctive\\:\\ 0\\.04970106565336229\ \(0\)\
\-\ laporte\\:\\ 0\\.04970106565336229\ \(0\)\
\-\ references\\:\\ 0\\.0495544971988234\ \(0\)\
\-\ coronal\\:\\ 0\\.04949847473045244\ \(0\)\
\-\ most\\:\\ 0\\.048522361105664845\ \(0\)\
\-\ includes\\:\\ 0\\.048333679359558034\ \(0\)\
\-\ range\\:\\ 0\\.04823371218044546\ \(0\)\
\-\ motion\\:\\ 0\\.04818407042672387\ \(0\)\
\-\ an\\:\\ 0\\.047537044306405256\ \(0\)\
\-\ leukopenia\\:\\ 0\\.047492021579597817\ \(0\)\
\-\ designated\\:\\ 0\\.047492021579597817\ \(0\)\
\-\ bursts\\:\\ 0\\.047492021579597817\ \(0\)\
\-\ surges\\:\\ 0\\.047492021579597817\ \(0\)\
\-\ exam\\:\\ 0\\.046934588016081434\ \(0\)\
\-\ on\\:\\ 0\\.046930992967665466\ \(0\)\
\-\ have\\:\\ 0\\.046576038644893444\ \(0\)\
\-\ radiographic\\:\\ 0\\.046115194678600875\ \(0\)\
\-\ laboratory\\:\\ 0\\.04513640905129444\ \(0\)\
\-\ involvement\\:\\ 0\\.04498765116279197\ \(0\)\
\-\ narrower\\:\\ 0\\.044708955184138026\ \(0\)\
\-\ treatment\\:\\ 0\\.044412817812498034\ \(0\)\
\-\ sclerosis\\:\\ 0\\.044272880469913095\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.04413538531942202\ \(0\)\
\-\ typically\\:\\ 0\\.04363469941284892\ \(0\)\
\-\ lymphoblastic\\:\\ 0\\.04287579621328994\ \(0\)\
\-\ which\\:\\ 0\\.04239492042761944\ \(0\)\
\-\ dosage\\:\\ 0\\.042148294078975516\ \(0\)\
\-\ fifty\\:\\ 0\\.042148294078975516\ \(0\)\
\-\ initial\\:\\ 0\\.04169710653107193\ \(0\)\
\-\ space\\:\\ 0\\.041374228208925994\ \(0\)\
\-\ vascular\\:\\ 0\\.0410349133683775\ \(0\)\
\-\ donald\\:\\ 0\\.04093256939694464\ \(0\)\
\-\ randomized\\:\\ 0\\.04041330304416638\ \(0\)\
\-\ implicated\\:\\ 0\\.04041330304416638\ \(0\)\
\-\ theory\\:\\ 0\\.039099410426096555\ \(0\)\
\-\ rheumatology\\:\\ 0\\.039099410426096555\ \(0\)\
\-\ age\\:\\ 0\\.03902260591321575\ \(0\)\
\-\ t1\\:\\ 0\\.03872752241568762\ \(0\)\
\-\ crescentic\\:\\ 0\\.03872352532318016\ \(0\)\
\-\ whose\\:\\ 0\\.03837190829178212\ \(0\)\
\-\ normal\\:\\ 0\\.038067259708794425\ \(0\)\
\-\ neck\\:\\ 0\\.038022988770792646\ \(0\)\
\-\ be\\:\\ 0\\.03782174632098515\ \(0\)\
\-\ resnick\\:\\ 0\\.03773020593144656\ \(0\)\
\-\ for\\:\\ 0\\.03767845129226573\ \(0\)\
\-\ pathogenesis\\:\\ 0\\.037156183609751245\ \(0\)\
\-\ erythematosus\\:\\ 0\\.036890366352332074\ \(0\)\
\-\ mechanisms\\:\\ 0\\.036890366352332074\ \(0\)\
\-\ secondary\\:\\ 0\\.0368418570458707\ \(0\)\
\-\ vincristine\\:\\ 0\\.03663691725697298\ \(0\)\
\-\ thirty\\:\\ 0\\.03663691725697298\ \(0\)\
\-\ buttock\\:\\ 0\\.036394736362213256\ \(0\)\
\-\ months\\:\\ 0\\.03618024140251365\ \(0\)\
\-\ anteroposterior\\:\\ 0\\.03616286421801765\ \(0\)\
\-\ co\\:\\ 0\\.03616286421801765\ \(0\)\
\-\ proposed\\:\\ 0\\.03594045892772037\ \(0\)\
\-\ detecting\\:\\ 0\\.03594045892772037\ \(0\)\
\-\ oct\\:\\ 0\\.03594045892772037\ \(0\)\
\-\ suppressed\\:\\ 0\\.03572677769540836\ \(0\)\
\-\ occurrence\\:\\ 0\\.03572677769540836\ \(0\)\
\-\ therapy\\:\\ 0\\.03571306854164668\ \(0\)\
\-\ history\\:\\ 0\\.035621199608105523\ \(0\)\
\-\ cell\\:\\ 0\\.035556509151570645\ \(0\)\
\-\ acetabular\\:\\ 0\\.03552116185768209\ \(0\)\
\-\ are\\:\\ 0\\.03537847414448237\ \(0\)\
\-\ fracture\\:\\ 0\\.03532580866186903\ \(0\)\
\-\ common\\:\\ 0\\.03524998131274826\ \(0\)\
\-\ corticosteroid\\:\\ 0\\.03513184105610032\ \(0\)\
\-\ trabecular\\:\\ 0\\.03513184105610032\ \(0\)\
\-\ patients\\:\\ 0\\.034966555921486626\ \(0\)\
\-\ lymphocytic\\:\\ 0\\.03494713953598677\ \(0\)\
\-\ methotrexate\\:\\ 0\\.03494713953598677\ \(0\)\
\-\ decreasing\\:\\ 0\\.03494713953598677\ \(0\)\
\-\ unclear\\:\\ 0\\.03494713953598677\ \(0\)\
\-\ abduction\\:\\ 0\\.03494713953598677\ \(0\)\
\-\ regimen\\:\\ 0\\.03442787318320851\ \(0\)\
\-\ complain\\:\\ 0\\.03442787318320851\ \(0\)\
\-\ saunders\\:\\ 0\\.033953820144253175\ \(0\)\
\-\ acute\\:\\ 0\\.03362441064834232\ \(0\)\
\-\ mineralization\\:\\ 0\\.03351773362164388\ \(0\)\
\-\ heads\\:\\ 0\\.03351773362164388\ \(0\)\
\-\ compromise\\:\\ 0\\.03351773362164388\ \(0\)\
\-\ 1998\\:\\ 0\\.03337979782255786\ \(0\)\
\-\ lucencies\\:\\ 0\\.03311398056513869\ \(0\)\
\-\ mentioned\\:\\ 0\\.032860531469779596\ \(0\)\
\-\ resonance\\:\\ 0\\.03261835057501986\ \(0\)\
\-\ preserved\\:\\ 0\\.03261835057501986\ \(0\)\
\-\ tissue\\:\\ 0\\.03260601578442793\ \(0\)\
\-\ locations\\:\\ 0\\.032501181047377405\ \(0\)\
\-\ ultimately\\:\\ 0\\.032501181047377405\ \(0\)\
\-\ or\\:\\ 0\\.032434825610999814\ \(0\)\
\-\ lupus\\:\\ 0\\.032386478430824255\ \(0\)\
\-\ demonstrate\\:\\ 0\\.03231355737808017\ \(0\)\
\-\ receiving\\:\\ 0\\.0322741409860242\ \(0\)\
\-\ groin\\:\\ 0\\.03216407314052697\ \(0\)\
\-\ magnetic\\:\\ 0\\.03205618500021892\ \(0\)\
\-\ indicative\\:\\ 0\\.03195039190821497\ \(0\)\
\-\ symptom\\:\\ 0\\.03164480678774871\ \(0\)\
\-\ journal\\:\\ 0\\.031546638851709774\ \(0\)\
\-\ philadelphia\\:\\ 0\\.03145020849280171\ \(0\)\
\-\ case\\:\\ 0\\.03122686163452541\ \(0\)\
\-\ subluxation\\:\\ 0\\.031170753748793377\ \(0\)\
\-\ directly\\:\\ 0\\.030904936491374206\ \(0\)\
\-\ consists\\:\\ 0\\.030904936491374206\ \(0\)\
\-\ sickle\\:\\ 0\\.03073466722618409\ \(0\)\
\-\ thigh\\:\\ 0\\.030569558437863496\ \(0\)\
\-\ bearing\\:\\ 0\\.030569558437863496\ \(0\)\
\-\ sensitive\\:\\ 0\\.030569558437863496\ \(0\)\
\-\ inner\\:\\ 0\\.030409306501255385\ \(0\)\
\-\ no\\:\\ 0\\.030318988482692606\ \(0\)\
\-\ patchy\\:\\ 0\\.030253633823624716\ \(0\)\
\-\ gestational\\:\\ 0\\.030177434357059784\ \(0\)\
\-\ make\\:\\ 0\\.030177434357059784\ \(0\)\
\-\ multifocal\\:\\ 0\\.030177434357059784\ \(0\)\
\-\ after\\:\\ 0\\.03015324515802286\ \(0\)\
\-\ prolonged\\:\\ 0\\.030102285951180592\ \(0\)\
\-\ accumulation\\:\\ 0\\.03002816000435436\ \(0\)\
\-\ zone\\:\\ 0\\.03002816000435436\ \(0\)\
\-\ duration\\:\\ 0\\.0299550290667625\ \(0\)\
\-\ humeral\\:\\ 0\\.0299550290667625\ \(0\)\
\-\ becomes\\:\\ 0\\.029741347834450496\ \(0\)\
\-\ suspicion\\:\\ 0\\.029535731996724216\ \(0\)\
\-\ frequency\\:\\ 0\\.029535731996724216\ \(0\)\
\-\ segmental\\:\\ 0\\.02946888240897311\ \(0\)\
\-\ seen\\:\\ 0\\.029262881820951093\ \(0\)\
\-\ nonspecific\\:\\ 0\\.029209396556156866\ \(0\)\
\-\ except\\:\\ 0\\.028961709675028903\ \(0\)\
\-\ vasculitis\\:\\ 0\\.028841964787826475\ \(0\)\
\-\ images\\:\\ 0\\.028751622475043478\ \(0\)\
\-\ year\\:\\ 0\\.02873321730604436\ \(0\)\
\-\ alcohol\\:\\ 0\\.02872479526018401\ \(0\)\
\-\ medication\\:\\ 0\\.02872479526018401\ \(0\)\
\-\ order\\:\\ 0\\.02872479526018401\ \(0\)\
\-\ suggests\\:\\ 0\\.02866714209734191\ \(0\)\
\-\ anemia\\:\\ 0\\.02855363438660509\ \(0\)\
\-\ part\\:\\ 0\\.027770253064516384\ \(0\)\
\-\ rotation\\:\\ 0\\.027673822705608316\ \(0\)\
\-\ systemic\\:\\ 0\\.027579069481713542\ \(0\)\
\-\ disorders\\:\\ 0\\.027439959633911052\ \(0\)\
\-\ therefore\\:\\ 0\\.027394367961599986\ \(0\)\
\-\ double\\:\\ 0\\.027394367961599986\ \(0\)\
\-\ end\\:\\ 0\\.02734915464777706\ \(0\)\
\-\ margin\\:\\ 0\\.027259838335208633\ \(0\)\
\-\ discussion\\:\\ 0\\.027215723332657978\ \(0\)\
\-\ recently\\:\\ 0\\.027128550704180823\ \(0\)\
\-\ embolization\\:\\ 0\\.02708548191825319\ \(0\)\
\-\ complains\\:\\ 0\\.02704275093020196\ \(0\)\
\-\ dislocation\\:\\ 0\\.026958281438990706\ \(0\)\
\-\ iii\\:\\ 0\\.026833983126493828\ \(0\)\
\-\ short\\:\\ 0\\.026712457499596623\ \(0\)\
\-\ phase\\:\\ 0\\.02659358355365537\ \(0\)\
\-\ tibia\\:\\ 0\\.026554528382485502\ \(0\)\
\-\ subsequently\\:\\ 0\\.026515751186419537\ \(0\)\
\-\ disorder\\:\\ 0\\.02628871112506633\ \(0\)\
\-\ disease\\:\\ 0\\.026091184094613588\ \(0\)\
\-\ sclerotic\\:\\ 0\\.02607075513926106\ \(0\)\
\-\ resulting\\:\\ 0\\.02586118418481105\ \(0\)\
\-\ marrow\\:\\ 0\\.025827026248171077\ \(0\)\
\-\ difficult\\:\\ 0\\.025793081134947507\ \(0\)\
\-\ femur\\:\\ 0\\.025496732817565745\ \(0\)\
\-\ children\\:\\ 0\\.025464778631843838\ \(0\)\
\-\ suspected\\:\\ 0\\.025464778631843838\ \(0\)\
\-\ via\\:\\ 0\\.025401427068641576\ \(0\)\
\-\ pre\\:\\ 0\\.025401427068641576\ \(0\)\
\-\ relatively\\:\\ 0\\.025307759895392815\ \(0\)\
\-\ test\\:\\ 0\\.025276891976855776\ \(0\)\
\-\ best\\:\\ 0\\.0250066792588935\ \(0\)\
\-\ increase\\:\\ 0\\.024948409472990627\ \(0\)\
\-\ caused\\:\\ 0\\.02491950663041634\ \(0\)\
\-\ 35\\:\\ 0\\.02491950663041634\ \(0\)\
\-\ limited\\:\\ 0\\.024805404595140072\ \(0\)\
\-\ administration\\:\\ 0\\.02474923736522622\ \(0\)\
\-\ al\\:\\ 0\\.02469364328030911\ \(0\)\
\-\ upon\\:\\ 0\\.024450260096446477\ \(0\)\
\-\ presenting\\:\\ 0\\.02434548430872103\ \(0\)\
\-\ et\\:\\ 0\\.02434548430872103\ \(0\)\
\-\ narrowing\\:\\ 0\\.024092035213361934\ \(0\)\
\-\ cells\\:\\ 0\\.02394543875358222\ \(0\)\
\-\ progressive\\:\\ 0\\.023802683694520155\ \(0\)\
\-\ use\\:\\ 0\\.02377925065604008\ \(0\)\
\-\ related\\:\\ 0\\.023617982174406603\ \(0\)\
\-\ change\\:\\ 0\\.023550302135766355\ \(0\)\
\-\ 18\\:\\ 0\\.023550302135766355\ \(0\)\
\-\ subsequent\\:\\ 0\\.023527927677019257\ \(0\)\
\-\ causes\\:\\ 0\\.023483452548015243\ \(0\)\
\-\ about\\:\\ 0\\.02326636514300857\ \(0\)\
\-\ pattern\\:\\ 0\\.023202890564282007\ \(0\)\
\-\ commonly\\:\\ 0\\.022996495692730472\ \(0\)\
\-\ fractures\\:\\ 0\\.022976279814071035\ \(0\)\
\-\ course\\:\\ 0\\.02295613867080824\ \(0\)\
\-\ studies\\:\\ 0\\.022797635185129023\ \(0\)\
\-\ appears\\:\\ 0\\.022758719497901553\ \(0\)\
\-\ compression\\:\\ 0\\.022758719497901553\ \(0\)\
\-\ diagnosed\\:\\ 0\\.02251232533787294\ \(0\)\
\-\ abnormalities\\:\\ 0\\.02251232533787294\ \(0\)\
\-\ above\\:\\ 0\\.02242044840425932\ \(0\)\
\-\ early\\:\\ 0\\.02240225749237572\ \(0\)\
\-\ presence\\:\\ 0\\.022330095204986015\ \(0\)\
\-\ including\\:\\ 0\\.022241216022682003\ \(0\)\
\-\ later\\:\\ 0\\.022241216022682003\ \(0\)\
\-\ risk\\:\\ 0\\.02220606639722802\ \(0\)\
\-\ 25\\:\\ 0\\.02201669534775412\ \(0\)\
\-\ weight\\:\\ 0\\.021672485758758457\ \(0\)\
\-\ was\\:\\ 0\\.02166223327437228\ \(0\)\
\-\ sign\\:\\ 0\\.02151591828776956\ \(0\)\
\-\ new\\:\\ 0\\.02150050618966239\ \(0\)\
\-\ less\\:\\ 0\\.02114312084322295\ \(0\)\
\-\ possible\\:\\ 0\\.02105732106924409\ \(0\)\
\-\ recent\\:\\ 0\\.021043151560482972\ \(0\)\
\-\ first\\:\\ 0\\.020972851578032838\ \(0\)\
\-\ internal\\:\\ 0\\.02094498362444403\ \(0\)\
\-\ cases\\:\\ 0\\.0209034471611387\ \(0\)\
\-\ along\\:\\ 0\\.02082131234354561\ \(0\)\
\-\ study\\:\\ 0\\.02072702763863876\ \(0\)\
\-\ right\\:\\ 0\\.02060752539287312\ \(0\)\
\-\ radiation\\:\\ 0\\.02059510417017687\ \(0\)\
\-\ several\\:\\ 0\\.020390453892585626\ \(0\)\
\-\ should\\:\\ 0\\.020278628855314527\ \(0\)\
\-\ superior\\:\\ 0\\.02020533394206999\ \(0\)\
\-\ differential\\:\\ 0\\.02019321341861124\ \(0\)\
\-\ any\\:\\ 0\\.020085325278303194\ \(0\)\
\-\ 20\\:\\ 0\\.020049832168749376\ \(0\)\
\-\ onset\\:\\ 0\\.019956299003766356\ \(0\)\
\-\ image\\:\\ 0\\.019875754323853186\ \(0\)\
\-\ clinical\\:\\ 0\\.01969600447672143\ \(0\)\
\-\ days\\:\\ 0\\.01967394706583298\ \(0\)\
\-\ usually\\:\\ 0\\.019564979972546324\ \(0\)\
\-\ proximal\\:\\ 0\\.01941599720768371\ \(0\)\
\-\ decreased\\:\\ 0\\.01925057507185928\ \(0\)\
\-\ demonstrated\\:\\ 0\\.019099924744137665\ \(0\)\
\-\ evaluation\\:\\ 0\\.018953328284357952\ \(0\)\
\-\ when\\:\\ 0\\.018773128589600428\ \(0\)\
\-\ level\\:\\ 0\\.018773128589600428\ \(0\)\
\-\ weeks\\:\\ 0\\.01862587170518233\ \(0\)\
\-\ however\\:\\ 0\\.018394756304240624\ \(0\)\
\-\ shows\\:\\ 0\\.018240309560560733\ \(0\)\
\-\ 10\\:\\ 0\\.018173047310582755\ \(0\)\
\-\ distal\\:\\ 0\\.018057300282438626\ \(0\)\
\-\ due\\:\\ 0\\.01786442445764434\ \(0\)\
\-\ one\\:\\ 0\\.017793820795082217\ \(0\)\
\-\ these\\:\\ 0\\.017549945763971366\ \(0\)\
\-\ prior\\:\\ 0\\.01738839780046504\ \(0\)\
\-\ over\\:\\ 0\\.017280935282050703\ \(0\)\
\-\ increased\\:\\ 0\\.016805700042147327\ \(0\)\
\-\ can\\:\\ 0\\.016308939491109804\ \(0\)\
\-\ other\\:\\ 0\\.0161394920334554\ \(0\)\
\-\ lateral\\:\\ 0\\.015423508239684256\ \(0\)\
\-\ presents\\:\\ 0\\.014950296033055257\ \(0\)\
\-\ has\\:\\ 0\\.01419568993881932\ \(0\)\
\-\ male\\:\\ 0\\.013837282025380242\ \(0\)\
\-\ by\\:\\ 0\\.013197674713348774\ \(0\)\
\-\ there\\:\\ 0\\.012365983549232327\ \(0\)\
\-\ from\\:\\ 0\\.01234300756136864\ \(0\)\
\-\ not\\:\\ 0\\.012268997802988221\ \(0\)\
\-\ at\\:\\ 0\\.011738690541511134\ \(0\)\
\-\ old\\:\\ 0\\.009197944954601644\ \(0\)\
